Page 55 - 南京医科大学自然科学版第1期
P. 55

第41卷第1期                           南京医科大学学报(自然科学版)
                  2021年1月                   Journal of Nanjing Medical University(Natural Sciences)     · 49  ·


               ·基础研究·

                伊立替康联合X线照射对人结肠癌细胞增殖和凋亡的影响



                席栋宾 ,张怀霞 ,徐玉珩 ,刘 毅 ,张延英                2*
                                       1
                              1
                      1
                                               1
                酒泉市人民医院胃肠外科,甘肃 酒泉               735000;甘肃中医药大学实验动物中心,甘肃             兰州 730000
                1                                     2
               [摘   要] 目的:探讨伊立替康(CPT⁃11)联合X线照射对人结肠癌细胞系HCT⁃116增殖和凋亡的影响。方法:采用MTT法检
                测不同浓度CPT⁃11(10、20、30、40、50 μg/mL)作用24 h以及单次不同剂量X线(3、6、9、12、15 Gy)照射对HCT⁃116增殖的影响;
                根据实验结果设计对照组、照射组和联合处理组,通过克隆形成实验检测3组细胞的增殖情况;采用AO/EB染色观察3组细胞
                的凋亡情况;通过Western blot实验检测各组p53和p21蛋白的水平。结果:在10~50 μg/mL范围内,CPT⁃11对于HCT⁃116细胞
                增殖呈剂量依赖性抑制作用;经10 μg/mL的CPT⁃11预处理后,分别联合3、6、9、12、15 Gy X 线照射,显示联合处理组增殖抑制
                率大于照射组,差异有统计学意义(P < 0.05);与对照组和照射组相比,联合处理组的集落形成数量明显减少(P < 0.05);联合
                处理组的p21和p53水平明显高于其余2组(P < 0.05),且凋亡率也显著增加,差异有统计学意义(P < 0.05)。结论:伊立替康
                联合X线照射抑制人结肠癌细胞系HCT⁃116的增殖,并诱导凋亡,可能与p53和p21的激活有关。
               [关键词] 结肠癌;伊立替康;细胞增殖;凋亡
               [中图分类号] R735.3                   [文献标志码] A                       [文章编号] 1007⁃4368(2021)01⁃049⁃05
                doi:10.7655/NYDXBNS20210109



                Effects of irinotecan combined with X ⁃ ray irradiation on proliferation and apoptosis of
                human colon cancer cells

                         1               1          1      1               2*
                XI Dongbin ,ZHANG Huaixia ,XU Yuheng ,LIU Yi ,ZHANG Yanying
                                                                                             2
                1 Department of Gastrointestinal Surgery,People’s Hospital of Jiuquan City,Jiuquan 735000;Animal Center,Gansu
                University of Chinese Medicine,Lanzhou 730000,China


               [Abstract] Objective:To investigate the effects of irinotecan(CPT⁃11)combined with X⁃ray treatment on the proliferation and
                apoptosis of human colon cancer cell line HCT⁃116. Methods:MTT method was used to detect the effects after treatment with different
                concentrations of CPT⁃11(10,20,30,40,50 μg/mL)for 24 hours and single dose of X⁃ray(3,6,9,12,15 Gy)on the proliferation of
                HCT⁃116. The proliferation rates of the three groups of cells were detected by clone formation assay,the apoptosis of the three groups
                was observed by AO/EB staining,and the levels of p53 and p21 protein were detected by Western blot. Results:CPT⁃11 inhibited the
                proliferation of HCT⁃116 cells in a dose⁃dependent manner in the range of 10~50 μg/mL. After pretreatment with CPT⁃11 at 10 μmol/L,
                combined 3,6,9,12 and 15 Gy X⁃ray irradiation showed that the inhibition rate of proliferation in the combined treatment group was
                higher than that in the irradiation group,and the difference was statistically significant(P < 0.05);compared with the control group and
                the irradiation group,the combined treatment group had a dose⁃dependent inhibition effect on the proliferation of HCT⁃116 cells. The
                number of colony formation decreased significantly(P < 0.05);the levels of p21 and p53 in the combined treatment group were
                significantly higher than those in the other two groups(P < 0.05),and the apoptotic rate also increased significantly(P < 0.05).
                Conclusion:Iritican combined with X⁃ray irradiation inhibits the proliferation and induces apoptosis of human colon cancer cell line
                HCT⁃116,which may be related to the activation of p53 and p21.
               [Key words] colon cancer;irinotecan;cell proliferation;apoptosis
                                                                              [J Nanjing Med Univ,2021,41(01):049⁃053]




               [基金项目] 中央引导地方科技发展专项
                ∗
                通信作者(Corresponding author),E⁃mail:1360599656@qq.com
   50   51   52   53   54   55   56   57   58   59   60